HCPCS Level II code J1303 denotes an injection of ravulizumab-cwvz, 10 mg, a long-acting monoclonal antibody used in specialty medicine. Nationally, accurate coding for high-cost injectable biologics like ravulizumab is important for claim adjudication, benefit design, and utilization management across commercial and public payers. Covered payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what J1303 represents clinically and operationally, plus what to expect when billing for an injected biologic therapy in outpatient infusion settings and physician offices. The publication highlights payer coverage patterns, reimbursement benchmarks, and relevant policy considerations affecting specialty drug administration. Clinical context covers the service type and typical sites of service where this injectable is administered. Where input data is unavailable, the report notes those gaps so readers can identify areas requiring payer-specific verification.